<DOC>
	<DOCNO>NCT01532544</DOCNO>
	<brief_summary>This investigator sponsor double-blinded , multinational , multi center , randomize ( 2:1 active : placebo ) , placebo-controlled , phase IIa trial severe pneumonia patient severe sepsis septic shock , investigate safety efficacy co-administration Iloprost escalating dos Eptifibatide continuous intravenous infusion totally 36 patient .</brief_summary>
	<brief_title>Integrilin Ilomedin Combination Comparison Standard Treatment Severe Pneumonia Patients With Severe Sepsis</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Eptifibatide</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . At least 18 year age AND 2 . Suspected proven bacterial pneumonia require administration antibiotic : Clinical diagnosis pneumonia , ( i.e . new increased cough , production purulent sputum change character sputum subject normally purulent sputum , typical auscultatory finding pneumonia chest examination ) : chest radiograph CT within last 24 hr show pulmonary infiltrate . 3 . Dyspnea and/or tachypnea ( &gt; 20 breaths/minute ) mechanical ventilation 4 . Two systemic inflammatory response syndrome ( SIRS ) criterion within last 24 hour : Temperature &lt; /= 36˚ C &gt; /= 38˚C Heart rate &gt; /= 90 beat per minute Mechanical ventilation acute respiratory process respiratory rate &gt; /= 20 breath per minute PaC02 &lt; 4.2 kPa WBC &gt; /= 12,000/mm³ OR &lt; /= 4,000/mm³ OR &gt; 10 % band 5 . At least one organ failure beyond respiratory failure ( cerebral , cardiovascular , hepatic , renal coagulation within last 24 hour ( &gt; 2 SOFA score specific organ system ) AND 6 . Can randomize trial dose &lt; 48 h severe sepsis diagnosis AND 7 . Consent obtainable 1 . Patient pregnant breastfeeding 2 . Patient weigh 125 kg 3 . Patients know allergy towards investigational product contraindication exclude accord investigational product specification 4 . Investigators clinical decision deem study participation favourable patient 5 . Patients clinician find antithrombotic therapy contraindicate prophylaxis include 6 . Patients increase risk bleeding : Surgery previous 12 h , expect surgery within 72 h , epidural spinal puncture previous 12 h , platelet count le 30,000/mm3 previous 24 h , INR 2.0 previous 24 h , need blood product bleed previous 24 h , treatment antithrombotics within 12 h ( profylaxis except ) , current previous intracranial bleeding traumatic brain spinal injury within last month . 7 . Patients require form antithrombotics ( beyond profylaxis ) therapeutic dos prothrombotics dose , include , unfractionated heparin within 8 hour infusion ( prophylactic heparin 15,000 U/day permit ) . Lowmolecularweight heparin within 12 hour ( prophylactic dos permit ) . exceed upper limit normal . Acetylsalicylic acid 650 mg/day within 3 day study . Thrombolytic therapy within 3 day study ( catheter clearance dos permit ) . Glycoprotein IIbIIIa antagonist within 7 day study . Antithrombin III dose great 10,000 U within 12 hour study . Protein C within 24 hour study . 8 . Previous diagnosed condition might mimic complicate course evaluation infectious disease process ( severe bronchiectasis , lung abcess empyema , aspiration pneumonia , active tuberculosis , pulmonary malignancy , cystic fibrosis , severe chronic interstitial pneumonia , COPD form chronic lung disease require home oxygen treatment result chronic CO2 retention , , etc . ) 9 . Patient expect survive 30 day uncorrectable medical surgical condition sepsis 10 . Patient acute chronic renal failure require dialysis ( renal failure without need dialysis permit ) . 11 . Patient hematological malignancy kind 12 . Patients undergone transplantation bone marrow , liver , pancreas , heart , lung , bowel ( kidney transplant permit ) 13 . Patient know hypercoagulable condition : APC resistance Hereditary protein C , protein S , antithrombin III deficiency Anticardiolipin antiphospholipid antibody Lupus anticoagulant Homocysteinemia Recent highly suspect pulmonary embolism deep venous thrombosis ( within 3 month ) 14 . Patients know congenital hypocoagulable disease 15 . Patient known AIDS 16 . Patient known primary pulmonary hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Severe pneumonia</keyword>
</DOC>